Scarica l'app Stockscreener
15.11
6.73%
-1.09
Tourmaline Bio Inc Borsa (TRML) Ultime notizie
BMO maintains $35 target on Tourmaline Bio, sees overreaction - Investing.com Australia
Tourmaline Bio stock holds $63 target post-Ph2 data By Investing.com - Investing.com Nigeria
BMO maintains $35 target on Tourmaline Bio, sees overreaction By Investing.com - Investing.com Nigeria
Tourmaline shares waver as investors mull mid-stage pacibekitug data - The Pharma Letter
In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD - insights.citeline.com
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition - Seeking Alpha
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga
Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff - BioPharma Dive
Tourmaline Bio (TRML) Shares Drop After Trial Data Release - GuruFocus
Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential - TipRanks
Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets - Endpoints News
Tourmaline Bio Says Pacibekitug Trial Showed 'Deep, Durable Reduction' in High-Sensitivity C-Reactive Protein - marketscreener.com
Transcript : Tourmaline Bio, Inc.Special Call - marketscreener.com
Tourmaline Bio Announces Positive Phase 2 Trial Results - TipRanks
Tourmaline Bio Reports Positive Topline Data From Phase 2 TRANQUILITY Study - Nasdaq
Tourmaline Bio stock slips after trial data (TRML:NASDAQ) - Seeking Alpha
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial - marketscreener.com
Tourmaline shares edge lower despite phase 2 trial results - Investing.com Australia
Tourmaline Bio Announces Positive Topline Results from the - GlobeNewswire
Tourmaline Bio to reveal Phase 2 trial results tomorrow By Investing.com - Investing.com South Africa
Tourmaline Bio to reveal Phase 2 trial results tomorrow - Investing.com Australia
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 - The Manila Times
Tourmaline Bio to Host Conference Call on Phase 2 TRANQUILITY Trial Results for Pacibekitug in Chronic Kidney Disease - Nasdaq
Major Phase 2 Trial Results Coming: Tourmaline Bio's Novel CKD Drug Could Transform Patient Care - Stock Titan
Tower Research Capital LLC TRC Increases Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Contrasting Fennec Pharmaceuticals (NASDAQ:FENC) and VectivBio (NASDAQ:VECT) - Defense World
Tourmaline Bio’s Pacibekitug: A Promising IL-6 Inhibitor for ASCVD with Strong Buy Rating - TipRanks
Raymond James Financial Inc. Takes Position in Commercial Vehicle Group, Inc. (NASDAQ:CVGI) - Defense World
Barclays PLC Increases Position in Chicago Atlantic Real Estate Finance, Inc. (NASDAQ:REFI) - Defense World
Barclays PLC Acquires 5,175 Shares of Tile Shop Holdings, Inc. (NASDAQ:TTSH) - Defense World
Barclays PLC Purchases Shares of 24,107 Grail, Inc. (NASDAQ:GRAL) - Defense World
Barclays PLC Acquires 42,792 Shares of MicroVision, Inc. (NASDAQ:MVIS) - Defense World
Tourmaline Bio (TRML) to Release Quarterly Earnings on Monday - Defense World
FY2025 EPS Estimates for Tourmaline Bio Decreased by Analyst - Defense World
Chardan Capital Raises Earnings Estimates for Tourmaline Bio - Defense World
FY2025 EPS Estimates for Tourmaline Bio Raised by Analyst - Defense World
Tourmaline Bio Q2 EPS Estimate Decreased by HC Wainwright - Defense World
Analysts Set Expectations for Tourmaline Bio Q2 Earnings - Defense World
HC Wainwright Predicts Tourmaline Bio Q2 Earnings - Defense World
Wells Fargo & Company MN Boosts Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio Reports Q1 2025 Financial Results - TipRanks
Tourmaline Bio’s (TRML) “Buy” Rating Reaffirmed at Chardan Capital - Defense World
Tourmaline Bio (NASDAQ:TRML) Receives “Buy” Rating from HC Wainwright - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Barclays PLC - Defense World
Invesco Ltd. Buys Shares of 15,602 Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Invesco Ltd. Purchases 1,181 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
CVS Health (NYSE:CVS) Price Target Raised to $71.00 - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of “Buy” from Brokerages - Defense World
Tourmaline Bio, Inc. SEC 10-Q Report - TradingView
Tourmaline (TRML) Projects Financial Stability into Late 2027 | TRML Stock News - GuruFocus
Tourmaline (TRML) Anticipates Key Data from Phase 2 Trial of Pacibekitug | TRML Stock News - GuruFocus
Tourmaline Bio, Inc. Confirms Progress in Phase 2 TRANQUILITY Trial and Financial Position Ahead of Key Data Readout - Nasdaq
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Tourmaline Bio Advances Key Cardiovascular Trial With $275M War Chest: Q2 Results Coming - Stock Titan
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Legal & General Group Plc - Defense World
Thyroid Eye Disease Treatment Market Size (7MM) was ~USD 1,993 - openPR.com
Palantir Technologies (PLTR) Receives a Sell from RBC Capital - The Globe and Mail
As the Market Fluctuates in Response to President Donald Trump's Tariffs, What Stocks Are Safe? - The Globe and Mail
Graves Disease Treatment Market 2034: EMA, PDMA, FDA Approvals, - openPR.com
Chardan Capital Weighs in on Tourmaline Bio FY2025 Earnings - Defense World
Best Stock to Buy Right Now: Costco vs. Realty Income - The Globe and Mail
Nasdaq (NDAQ) Gets a Buy from Barclays - The Globe and Mail
AGNC Investment Expects to Capitalize on Wide Spreads. But Is the High-Yield Dividend Stock a Buy? - The Globe and Mail
Chardan Capital Begins Coverage on Tourmaline Bio (NASDAQ:TRML) - Defense World
Ready to Jump After Recent Trade: Tourmaline Bio Inc (TRML) - Sete News
1.52%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):